This immunological quiescence is often achieved through the dysregulation of the antigen processing and presentation (APP) pathway (1), which can dramatically reduce tumor-associated antigen (TAA) and neoantigen presentation by HLA-I (3). This evidence concerns the gene APP and neoplasm.